

3 may also be utilized. As a consequence, GPCR signaling events have predominantly been measured via quantification of these second messenger products.--

Delete the first full paragraph, at page 4, lines 3-6 and insert therefor the following:

--Efforts such as the Human Genome Project are identifying new GPCRs ("orphan" receptors) whose physiological roles and ligands are unknown. It is estimated that several thousand GPCRs exist in the human genome.--

Delete the first paragraph, at page 10, lines 1-9 and insert therefor the following:

--FIGURE 3. Interaction of activated receptor $\beta 2AR$ and arrestin can be measured by β -galactosidase complementation. Figure 3A shows a time course of β -galactosidase activity in response to agonist (-)isoproterenol stimulation in C2 expressing $\beta 2AR$ - $\beta gal\Delta\alpha$ ($\beta 2AR$ alone, in expression vector pICAST ALC), or C2 clones, and a pool of C2 co-expressing $\beta 2AR$ - $\beta gal\Delta\alpha$ and $\beta Arr2$ - $\beta gal\Delta\omega$ (in expression vectors pICAST ALC and pICAST OMC). Figure 3B shows a time course of β -galactosidase activity in response to agonist (-)isoproterenol stimulation in C2 cells expressing $\beta 2AR$ alone (in expression vector pICAST ALC) and C2 clones co-expressing $\beta 2AR$ and $\beta Arr1$ (in expression vectors ICAST ALC and pICAST OMC).--

Delete the second full paragraph, at page 11, lines 7-12 and insert therefor the following:

--FIGURE 7. Agonist stimulated cAMP response in C2 cells co-expressing Dopamine receptor D1 ($D1$ - $\beta gal\Delta\alpha$) and β -arrestin-2 ($\beta Arr2$ - $\beta gal\Delta\omega$). The clone expressing $\beta Arr2$ - $\beta gal\Delta\omega$ ($Arr2$ alone) was used as a negative control in the assay. Cells expressing $D1$ - $\beta gal\Delta\alpha$ in addition to $\beta Arr2$ - $\beta gal\Delta\omega$ responded to treatment with agonist (3-hydroxytyramine

cut
a4 hydrochloride at 3 μ M) . D1(PIC2) or D1(PIC3) designate D1 in expression vector pICAST
ALC2 or pICAST ALC4, respectively.--

Delete the fifth full paragraph, at page 14, lines 19-20 and insert therefor the following:

a5 --FIGURE 23. A schematic depicting the method of the invention, which shows that two
inactive mutants become active when they interact.--

Delete the second paragraph, at page 15, lines 3-15 and insert therefor the following:

a6 --The present invention provides a method to interrogate GPCR function and pathways.
The G-protein-coupled superfamily continues to expand rapidly as new receptors are
discovered through automated sequencing of cDNA libraries or genomic DNA. It is estimated
that several thousand GPCRs may exist in the human genome. Only a portion have been cloned
and even fewer have been associated with ligands. The means by which these, or newly
discovered orphan receptors, will be associated with their cognate ligands and physiological
functions represents a major challenge to biological and biomedical research. The identification
of an orphan receptor generally requires an individualized assay and a guess as to its function.
The interrogation of a GPCR's signaling behavior by introducing a replacement receptor
eliminates these prerequisites because it can be performed with and without prior knowledge of
other signaling events. It is sensitive, rapid and easily performed and should be applicable to
nearly all GPCRs because the majority of these receptors should desensitize by a common
mechanism.--

Delete the fourth paragraph, at page 16, lines 13-20 and insert therefor the following:

a
7

--The present invention involves a method for monitoring protein-protein interactions in GPCR pathways as a complete assay using ICAST™ (Intercistronic Complementation Analysis Screening Technology as disclosed in pending U.S. patent application serial no. 053,614, filed April 1, 1998, ^{new U.S. Patent No. 6,342,345 B1,} the entire contents of which are incorporated herein by reference). This invention enables an array of assays, including GPCR binding assays, to be achieved directly within the cellular environment in a rapid, non-radioactive assay format amenable to high-throughput screening. Using existing technology, assays of this type are currently performed in a non-cellular environment and require the use of radioisotopes.--

3-8-02
a

Delete the fifth paragraph, at page 16, line 21-page 17, line 11 and insert therefor the following:

a
8

The present invention combined with Tropix ICAST™ and Advanced Discovery Sciences™ technologies, e.g., ultra high-throughput screening, provide highly sensitive cell-based methods for interrogating GPCR pathways which are amendable to high-throughput screening (HTS). These methods are an advancement over the invention disclosed in U.S. Patent 5,891,646, which relies on microscopic imaging of GPCR components as fusion with Green-fluorescent-protein. Imaging techniques are limited by low-throughput, lack of thorough quantification and low signal to noise ratios. Unlike yeast-based-2-hybrid assays used to monitor protein/protein interactions in high-throughput assays, the present invention is applicable to a variety of cells including mammalian cells, plant cells, protozoa cells such as E. coli and cells of invertebrate origin such as yeast, slime mold (*Dictyostelium*) and insects;

cr+
ag detects interactions at the site of the receptor target or downstream target proteins rather than in the nucleus; and does not rely on indirect read-outs such as transcriptional activation. The present invention provides assays with greater physiological relevance and fewer false positives.

Delete the first full paragraph, at page 17, lines 12-22 and insert therefor the following:

a
9 --Advanced Discovery Sciences™ is in the business of offering custom-developed screening assays optimized for individual assay requirements and validated for automation. These assays are designed by HTS experts to deliver superior assay performance. Advanced Discovery Sciences™ custom assay development service encompasses the design, development, optimization and transfer of high performance screening assays. Advanced Discovery Sciences™ works to design new assays or convert existing assays to ultra-sensitive luminescent assays ready for the rigors of HTS. Among some of the technologies developed by Advanced Discovery Sciences™ are the cAMP-Screen™ immunoassay system. This system provides ultrasensitive determination of cAMP levels in cell lysates. The cAMP-Screen™ assay utilizes the high-sensitivity chemiluminescent alkaline phosphatase (AP) substrate CSPD® with Sapphire-II™ luminescence enhancer.--

Delete the first paragraph, at page 18, lines 2-14 and insert therefor the following:

a
10 --GPCR activation can be measured through monitoring the binding of ligand-activated GPCR by an arrestin. In this assay system, a GPCR, e.g. β -adrenergic receptor (β 2AR) and a β -arrestin are co-expressed in the same cell as fusion proteins with β -gal mutants. As illustrated in Figure 1, the β 2AR is expressed as a fusion protein with $\Delta\alpha$ form of β -gal mutant (β 2ADR $\Delta\alpha$) and the β -arrestin as a fusion protein with the $\Delta\omega$ mutant of β -gal (β -Arr $\Delta\omega$). The two fusion

proteins exist inside of a resting (or un-stimulated) cell in separate compartments, i.e. membrane for GPCR and cytosol for arrestin, and they cannot form an active β -galactosidase enzyme.

When such a cell is treated with an agonist or a ligand, the ligand-occupied and activated receptor will become a high affinity binding site for Arrestin. The interaction between an activated $\beta 2\text{ADR}\Delta\alpha$ and $\beta\text{-Arr}\Delta\omega$ drives the β -gal mutant complementation. The enzyme activity can be measured by using an enzyme substrate, which upon cleavage releases a product measurable by colorimetry, fluorescence, chemiluminescence (e.g. Tropix product GalScreen®).--

Delete the first full paragraph, at page 19, lines 2-12 and insert therefor the following:

--3. In the last step, the cells expressing both $\beta 2\text{ADR}\Delta\alpha$ and $\beta\text{Arr}2\Delta\omega$ were tested for response by agonist/ligand stimulated β -galactosidase activity. Triplicate samples of cells were plated at 10,000 cells in 100 microliter volume into a well of 96-well culture plate. Cells were cultured for 24 hours before assay. For an agonist assay (Figures 3 and 4), cells were treated with variable concentrations of agonist, for example, (-) isoproterenol, procaterol, dobutamine, terbutaline or L-phenylephrine for 60 min at 37° C. The induced β -galactosidase activity was measured by addition of Tropix GalScreen® substrate (Applied Biosystems) and luminescence measured in a TR717™ luminometer (Applied Biosystems). For antagonist assay (Figure 5), cells were pre-incubated for 10 min in fresh medium without serum in the presence of ICI-118,551 or propranolol followed by addition of 10 micromolar (-) isoproterenol.--